Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany's Apogenix has secured an additional €2.3m BMBF grant (German Federal Ministry of Education and Research) to further advance its lead substance APG101, used to treat myelodysplastic syndromes (MDS).
Subscribe to our email newsletter
APG101, a first-in-class, fully human protein is an inhibitor of the CD95 ligand (CD95L).
The company will use the proceeds to develop APG101, and for the production of clinical material and development of a biomarker program.
Apogenix CEO and CFO Thomas Höger said the grant, along with the grants they have been awarded over the last five years totaling more than €6m, helps to develop their lead substance APG101 for the treatment of life-threatening diseases with a high unmet medical need.
”This allows us to develop APG101 for a new, promising indication, namely MDS. We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-of-concept in a phase II trial planned for 2013," Höger added.
Apogenix plans to commence Phase II trial for the treatment of MDS in 2013.